

Future drug target gag Polyprotein Isolate Eli of HIV-1 group M subtype H 3D structure by threading assembly refinement– A bioinformatics approach

Undety Benjamin Jason^{1*}, Daniel Alex Anand²

¹Department of Bioinformatics, Sathyabama University, Chennai, India,

²Department of Biomedical Engineering, Sathyabama University, Chennai, India

*Corresponding author: E.Mail: ubjason@gmail.com; Cell: 8015819602

ABSTRACT

The research of a potential drug to inhibit replication of HIV-1 is increasing with the increase of drug resistance. Drugs existing are targets three enzymes reverse transcriptase, integrase and protease. GAG gene out of nine genes of HIV genome is found conserve. The functional conservation of HIV-1 Gag gene implies drug design targeting Gag (Guangdi, 2013). HIV-1 replication may be blocked by targeting gag polyprotein an alternative strategy for novel drug class for the HIV-1 treatment. Gag gene is responsible to form capsule to the virus. But targeting Gag is not possible as is now to determine the structure of Gag poly-protein as it is undetermined still. The crystal structure of gag is not available in PDB database. The gag polyprotein of Human immunodeficiency virus type 1 group M subtype H (isolate ELI) (HIV-1) is downloaded for three dimensional structure determinations. The unavailability of a close template is an added challenge for alternative structure prediction.

KEYWORDS: Conservation, gag polyprotein, target, template.

1. INTRODUCTION

HIV-1, which causes acquired immune deficiency syndrome (AIDS), is a retrovirus in genus Lentiviridae. HIV-1 is an enveloped virus which encodes two envelope (Env) glycoproteins - the surface (SU) glycoprotein gp120 and a transmembrane (TM) glycoprotein gp41, Gag has four major proteins, they are matrix (MA), capsid (CA), nucleocapsid (NC), and p6—and the pol-encoded enzymes protease (PR), reverse transcriptase (RT), and integrase (IN). HIV-1 also encodes two regulatory proteins, they are Tat and Rev and several accessory proteins, they are Vpu, Vif, Nef, and Vpr. The genome is pseudodiploid which is composed of two single strands of RNA linked in dimer. The HIV-1 infection initiates with the attachment of gp120 to target cell plasma membrane (Guangdi, 2013). The principal attachment of the receptor for HIV-1 and other primate lentiviruses is CD4. Productive infection also requires the presence of a co-receptor, they are typically CXCR4 or CCR5. The binding of gp120 to CD4 and co-receptor initiates conformational changes in gp41, which in turn directs to fusion of the viral envelope and the target cell membrane and entry of the viral core into the host cell cytoplasm. Recent evidence suggests that HIV-1 entry can also occur in a low-pH endosomal compartment after receptor-mediated endocytosis (Miyachi et al, 2009). Upon entry of the virion into the cytosol, the Env glycoproteins and the lipid-associated MA protein dissociate from the incoming particle at the membrane, and the poorly understood process of uncoating is initiated. The enzymes RT and IN, together with the NC protein, remain in close association with the viral RNA as it is converted to double-stranded DNA by RT-catalyzed reverse transcription (Telesnitsky et al., 1997). NC acts as a nucleic acid chaperone at several steps during reverse transcription to facilitate the conversion of RNA to DNA (Levin, 2005). Vpr is also a component of the reverse transcription complex (RTC). The extent to which CA remains associated with the incoming RTC has been a topic of debate. However, reverse transcription and uncoating appear to be temporally linked (Hulme A E et al, 2011), and it is clear that some host restriction factors that block early postentry steps in the viral replication cycle target CA (Towers GJ, 2007). The newly reverse transcribed viral DNA is translocated to the nucleus in a structure known as the preintegration complex (PIC). The nuclear import process remains incompletely understood; however, a role for CA in this process (Dismuke and Aiken, 2006; Yamashita and Emerman, 2004) implies that some CA protein may remain associated with the viral nucleoprotein complex as it traffics to the nuclear pore. Once inside the nucleus, the double-stranded viral DNA integrates into the target cell genome through the action of the IN enzyme (Brown, 1997). The integrated viral DNA serves as the template for transcription from the viral promoter in the 5' long terminal repeat (LTR) to generate the spliced viral mRNAs and full-length genomic RNAs; these are transported out of the nucleus via the action of the Rev protein. The Gag proteins are translated from full-length message as a polyprotein precursor containing MA, CA, NC, and p6 domains as well as two spacer peptides, SP1 and SP2. During translation of the Gag precursor, known as Pr55^{Gag}, an occasional 1 ribosomal frameshift leads to the production of a GagPol precursor protein (Pr160^{GagPol}), the abundance of which is approximately 5% that of Pr55^{Gag}. The Gag and GagPol precursor polyproteins are transported to the plasma membrane, where they assemble and incorporate the viral Env glycoproteins. The membrane targeting of Gag and GagPol is regulated by the MA domain, which also plays an important role in the incorporation of the viral Env glycoproteins. Assembly takes place in cholesterol-rich membrane microdomains (lipid rafts) through direct interactions between MA and the phospholipid phosphatidylinositol-4,5-bisphosphate [PI(4,5)P₂]. Interactions within the CA domain of Gag initiate the Gag assembly process.

The Gag gene of HIV-1 expressed MA (p17), CA (p24), SP1 (p2), NC (p7), SP2 (p1) and P6. HIV p6 is a 6 kDa polypeptide at the N-terminus of the Gag polyprotein. It recruits cellular proteins Tsg101 (a component of ESCRT-1) and Alix to initiate virus particle budding from the plasma membrane. p6 has no known function in the mature virus. P6 protein was taken to study its variance in sequence and structural levels. Gag proteins play a vital role in virus assembly, release, maturation, function in the establishment of a productive HIV 1 and which as also Viral structural proteins. In spite of their vital

role throughout the replication cycle, there are currently no approved antiretroviral therapies that target the Gag precursor protein or any of the mature Gag proteins. Recent progress in understanding the structural and cell biology of HIV-1 Gag function has revealed a number of potential Gag-related targets for possible therapeutic intervention. In this study, we emphasize that our current understanding of HIV-1 Gag P6 protein suggest some approaches to be as a target for novel antiretroviral agents.

2. MATERIALS AND METHODS

Sequence of Gag Poly Protein: The gag polyprotein of **Human immunodeficiency virus type 1 group M subtype H (isolate ELI) (HIV-1)** is downloaded for three dimensional structure determinations. Its length is 500 amino acids. The Gag polyprotein sequence is retrieved from the Uniprot database, >sp|P04592|GAG_HV1EL Gag polyprotein OS=Human immunodeficiency virus type 1 group M subtype D (isolate ELI) GN=gag PE=3 SV=3
 MGARASVLSGGKLDKWEKIRLRPGGKKKYRLKHIVWASRELERALNPGLLETSEGCK
 QIIGQLQPAIQTGTEELRSLYNTVATLYCVHKGIDVKDTKEALEKMEEEQNKSKKKAQQAAADTGNNNSQVSNYPYIV
 QNLQGMVHQAIAPRPTLNWVVKVIEEKAFSPEVPMFSALSEGATPQDLNMLNTVGGHQAAMQMLKETINEEAAE
 WDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIAWMTSNPPPIVGEIYKRWIIVGLNKKIVRMYSVPSILDIRQGPKE
 PFRDYVDRFYKTLRAEQASQDVKNWMTETLLVQANPDCCKTILKALGPQATLEEMMTACQGVGGPSHKARVLAEA
 MSQATNSVTTAMMQRGNFKGPRKIIKFCNCGKEGHIKNCRAPRKKGCWRCGKEGHQLKDCTERQANFLGRIWPSH
 KGRPGNLFQSRPEPTAPPAESFGFGEEITPSQKQEQKDKELYPLTSLKSLFGNDPLSQ

A hierarchical protein structure modeling approach is used on the secondary-structure enhanced profile-profile threading alignment and the iterative implementation of the threading assembly refinement program. Critical Assessment of Structure Prediction (CASP) experiment implemented. CASP (or Critical Assessment of Techniques for Protein Structure Prediction) is a community-wide experiment for testing the state-of-the-art of protein structure predictions which takes place every two years since 1994. The experiment (often referred as a competition) is strictly blind because the structures of testing proteins are unknown to the predictors.

3. RESULTS AND DISCUSSION

The software first retrieves template proteins of similar folds (or super-secondary structures) from the PDB library by LOMETS, a locally installed meta-threading approach. Then the continuous fragments excised from the PDB templates are reassembled into full-length models by replica-exchange Monte Carlo simulations with the threading unaligned regions (mainly loops) built by ab initio modeling. In cases where no appropriate template is identified by LOMETS, I-TASSER will build the whole structures by ab initio modeling. The low free-energy states are identified by SPICKER through clustering the simulation decoys. In the third step, the fragment assembly simulation is performed again starting from the SPICKER cluster centroids, where the spatial restraints collected from both the LOMETS templates and the PDB structures by TM-align are used to guide the simulations. The purpose of the second iteration is to remove the steric clash as well as to refine the global topology of the cluster centroids. The decoys generated in the second simulations are then clustered and the lowest energy structures are selected. The final full-atomic models are obtained by REMO which builds the atomic details from the selected I-TASSER decoys through the optimization of the hydrogen-bonding network. The three dimensional structure is determined with the 89.8% of amino acids in favored regions evaluated by Ramachandran plot through Rampage.



Figure.1. Constructed three dimensional structure of Gag Polyprotein isolate ELI

The best predicted model evaluated by Rampage, University of Cambridge is shown in Figure.3&4 which was found to have best score being validated out of the five models. Figure.2 shows the accuracy of each residue forming a helix, beta strand or a coil.




Figure 2. Representation of each residue accuracy forming secondary structure




Figure 3. Ramachandran diagram of the best model




Figure 4. Residues in the allowed and outlier regions

Number of residues in favoured region (~98.0% expected): 447 (89.8%)

Number of residues in allowed region (~2.0% expected): 27 (5.4%)

Number of residues in outlier region : 24 (4.8%)

4. CONCLUSION

The drug resistance to Anti-retroviral therapy targeting mostly RT and IN has directed to study Gag poly protein. The Gag polyprotein was understood to be conserved and implicates rational drug design. As it forms the encapsulation of HIV, if blocked it allows core viral ingredients to fatal end. The non availability of PDB structure and similar template with higher number of residues caused to use threading assembly refinement. This work further carries in finding active site, lead screening and docking studies of Gag poly protein.

REFERENCES

- Ambrish Roy, Alper Kucukural, Yang Zhang, I-TASSER: a unified platform for automated protein structure and function prediction, *Nature Protocols*, 5, 2010, 725-738.
- Ambrish Roy, Jianyi Yang, Yang Zhang. COFACTOR: an accurate comparative algorithm for structure-based protein function annotation. *Nucleic Acids Research*, 40, 2012, 471-477.
- Brown P O: Integration. In: *Retroviruses* (Coffin J, Varmus H, Hughes S, eds.). Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1997, 161–205.
- Chiu H C, Wang F D, Chen Y M, Wang C T, Effects of human immunodeficiency virus type 1 transframe protein p6* mutations on viral protease-mediated Gag processing, *J Gen Virol*, 87, 2006, 2041-6.
- Dismuke D J and Aiken C: Evidence for a functional link between uncoating of the human immunodeficiency virus type 1 core and nuclear import of the viral preintegration complex, *J Virol*, 80(8), 2006, 3712–3720.
- Guangdi Li, Jens Verheyen, Soo-Yon Rhee, Arnout Voet, Anne-Mieke Vandamme, Krist of heys: Functional conservation of HIV-1 Gag: implications, *Retrovirology*, 10, 2013, 126.
- Huang M, Orenstein J M, Martin M A, Freed E O, p6 Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease, *J Virol*, 69(11), 1995, 6810-8.
- Hulme A E, Perez O, and Hope T J: Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription, *Proc Natl Acad Sci USA*, 108(24), 2011, 9975–9980.
- Levin J G, Guo J, Rouzina I, and Musier-Forsyth K: Nucleic acid chaperone activity of HIV-1 nucleocapsid protein: Critical role in reverse transcription and molecular mechanism. *Prog Nucleic Acid Res Mol Biol*, 80, 2005, 217–286.

Lovell S.C, Davis I.W, Arendall III W.B, de Bakker P.I.W, Word J.M, Prisant M.G, Richardson J.S and Richardson D.C (2002), Structure validation by Calpha geometry: phi,psi and Cbeta deviation. *Proteins: Structure, Function & Genetics*. 50, 2002, 437-450.

Melikyan G B, Common principles and intermediates of viral protein-mediated fusion: The HIV-1 paradigm, *Retrovirology*, 5, 2008, 111.

Miyauchi K, Kim Y, Latinovic O, Morozov V, and Melikyan GB: HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes, *Cell*, 137(3), 2009, 433–444.

Telesnitsky A and Goff S P, Reverse transcriptase and the generation of retroviral DNA. In: *Retroviruses* (Coffin J, Varmus H, Hughes S, eds.). Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1997, 121–160.

Towers GJ: The control of viral infection by tripartite motif proteins and cyclophilin A. *Retrovirology*, 4, 2007, 40.

Wu S T, Zhang Y: LOMETS: A local meta-threading-server for protein structure prediction.

Yamashita M and Emerman M: Capsid is a dominant determinant of retrovirus infectivity in nondividing cells, *J Virol*, 78(11), 2004, 5670–5678.